Income statement
CAD
Annual
| Metric | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|
| Revenue | 1M | 112K | 0 | 0 | 0 |
| Gross Profit | 801K | 15K | 0 | 0 | 0 |
| Operating Income | -17M | -642K | -71K | -83K | -76K |
| EBITDA | -27M | -3M | -81K | -76K | -62K |
| Net Income | -30M | -3M | -81K | -76K | -61K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.00001
+0.00% today
1Y Change
+0.00%
Window
Jun 20, 2025 → Jun 18, 2026
Coverage: 250 bars · Jun 20, 2025 → Jun 18, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
RavenQuest BioMed Inc. (RVVQF) is a Healthcare stock with listed on OTC. The stock last traded around $0.00 and up 0.0% across the available one-year price window (Jun 20, 2025 → Jun 18, 2026). Baseline metrics include revenue growth of +1018.8%, EPS growth of -230.0%, a dividend yield of 0.0%. What stands out right now is revenue +1018.8%, EPS -230.0%, free cash flow -830.2% with operating margin -1366.4% and ROIC -47.3%. Valuation is more restrained than many high-expectation growth names at price/sales 0.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines RVVQF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
RVVQF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
RVVQF Max Drawdown
0.00%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for RVVQF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$0.0
FY Net Income
-$60.6K
+20.3% YoY
Free Cash Flow
-$36.6K
-85.8% YoY
Revenue Growth
+1018.8%
EPS Growth
-230.0%
Gross Margin
63.7%
Net Margin
-2423.9%
Income statement
CAD
| Metric | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|
| Revenue | 1M | 112K | 0 | 0 | 0 |
| Gross Profit | 801K | 15K | 0 | 0 | 0 |
| Operating Income | -17M | -642K | -71K | -83K | -76K |
| EBITDA | -27M | -3M | -81K | -76K | -62K |
| Net Income | -30M | -3M | -81K | -76K | -61K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
CAD
| Metric | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|
| Cash & Equivalents | 363K | 3M | 604 | 2K | 9K |
| Total Assets | 38M | 9M | 9K | 8K | 14K |
| Total Liabilities | 15M | 1M | 459K | 377K | 306K |
| Shareholder Equity | 22M | 8M | -450K | -369K | -293K |
| Total Debt | 13M | 233K | 84K | 52K | 40K |
| Net Debt | 13M | -3M | 83K | 51K | 31K |
Cash flow positioning
Latest Full Year
Operating Cash Flow
37K
-85.8% YoY
Capital Expenditures
0
Free Cash Flow
37K
-85.8% YoY
Key ratios
Gross Margin
63.7%
Operating Margin
-1366.4%
Net Margin
-2423.9%
ROE
-203.4%
Debt / Equity
0.59x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.